EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Understanding the landscape of immunotherapy in thymic epithelial tumors

Rohan Maniar iD, Patrick J Loehrer

Cancer · 15.04.2023 · 129 (8) · 1162-1172

DOI: 10.1002/cncr.34678 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 19.02.2023. Verfasst von Rohan Maniar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology & Oncology, Indiana University School of Medicine, Indiana Cancer Pavilion, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Thymoma, Thymus Neoplasms, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thymic epithelial tumors (TETs) are a rare group of malignancies arising from the thymus. Surgery remains the foundation of treatment for patients with early‐stage disease. Limited treatment options are available for the treatment of unresectable, metastatic, or recurrent TETs and are associated with modest clinical efficacy. The emergence of immunotherapies in the treatment of solid tumors has generated significant interest in understanding their role in TET treatment. However, the high rates of comorbid paraneoplastic autoimmune disorders, particularly in thymoma, have tempered expectations regarding the role of immune‐based therapies. Clinical studies of immune checkpoint blockade (ICB) in thymoma and thymic carcinoma have revealed higher frequencies of immune‐related adverse events (IRAEs) and limited efficacy. Despite these setbacks, the growing understanding of the thymic tumor microenvironment and systemic immune system has advanced the understanding of these diseases and provided opportunities for novel immunotherapy modalities. Ongoing studies are evaluating numerous immune‐based treatments in TETs with the goal of improving clinical efficacy and mitigating IRAE risk. This review will provide insight into the current understanding of the thymic immune microenvironment, outcomes of previous ICB studies, and review treatments currently being explored for the management of TET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThymomaThymus NeoplasmsNeoplasms, Glandular and EpithelialHumansImmunotherapyImmune Checkpoint InhibitorsTumor Microenvironment

Stichwörter der Autor:innen

immune checkpoint blockadeimmunotherapythymic carcinomathymomatumor immune microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology & Oncology, Indiana University School of Medicine, Indiana Cancer Pavilion, Indianapolis, Indiana, USA.

ORCID-Profile: Rohan Maniar

Förderung

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Zitieren

APA

Maniar, R., & Loehrer, P. J. (2023). Understanding the landscape of immunotherapy in thymic epithelial tumors. Cancer, 129(8), 1162-1172. https://doi.org/10.1002/cncr.34678

Vancouver

Maniar R, Loehrer PJ. Understanding the landscape of immunotherapy in thymic epithelial tumors. Cancer. 2023;129(8):1162-1172. doi:10.1002/cncr.34678

BibTeX
@article{Maniar2023,
  author = {Maniar, Rohan and Loehrer, Patrick J},
  title = {Understanding the landscape of immunotherapy in thymic epithelial tumors},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {8},
  pages = {1162--1172},
  doi = {10.1002/cncr.34678}
}
Kostenlos starten →